Abstract
Posttranslational Protein Modifications: Current Implications for Cancer Detection, Prevention, and Therapeutics
Highlights
Over the last several years major advances in sensitive high throughput technologies have been made in the fields of genomics and proteomics
The goals of this meeting were to address several topics where posttranslational modification (PTM) play roles in cancer progression, consider what technologies can be applied to clinical prevention or detection of cancer, and assess what PTMs could be pursued for development of promising surrogate markers
Since that time some advancement has been made in technological developments to study PTMs, identifying the central roles they play in cancer progression, From the Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health, Bethesda, Maryland 20892-7362
Summary
Over the last several years major advances in sensitive high throughput technologies have been made in the fields of genomics and proteomics. To draw greater attention to the opportunities afforded by innovative research in PTMs, a 2-day workshop was conducted August 2002 in Bethesda, MD The goals of this meeting were to address several topics where PTMs play roles in cancer progression, consider what technologies can be applied to clinical prevention or detection of cancer, and assess what PTMs could be pursued for development of promising surrogate markers. Research in PTM as it relates to biomarker discovery has required the study of discreet modifications on specific proteins of importance to cancer biology This one by one approach clearly takes time, but the rewards are not to be underestimated in terms of application to cancer detection and treatment. PTMs that are currently most germane to clinical applications in cancer medicine are briefly introduced below
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have